Potent Ventures Receives Conditional Approval from the Canadian Securities Exchange for the Change of Business to the Gummy Project Biotech Investing
ABBV Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 6, 2022 Deadline in Securities Fraud Class Action Lawsuit Against AbbVie, Inc. Pharmaceutical Investing
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd. Buyout Life Science Investing
CLASS ACTION UPDATE for ABBV, BKKT and MULN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
CLASS ACTION UPDATE for IBM, SDIG and AUPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials Pharmaceutical Investing
Upadacitinib Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease Pharmaceutical Investing
Johnson & Johnson Appoints Thibaut Mongon as CEO Designate of Planned New Consumer Health Company Pharmaceutical Investing
BIOHAVEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Biohaven Pharmaceutical Holding Company Ltd. - BHVN Life Science Investing
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
